Alvarez Secord A et al. PICCOLO: An open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression. SGO 2022;Abstract 300.
Arend RC et al. Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018). ASCO 2023;Abstract 5505.
Bannerjee S et al. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. ESMO 2022;Abstract 529MO.
Coleman R et al. Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRa) expression: Evaluation of sequence of therapy in anti-tumor activity in the SORAYA study. SGO 2023;Abstract 139.
Coleman RL et al. Overall survival results from ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. IGCS 2022;Abstract O003.
DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract
González-Martín AJ et al. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. Eur J Cancer 2022;174:221-31. Abstract
Gonzalez Martin AJ et al. PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. ESMO 2022;Abstract 530P.
Hardesty MM et al. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 2022;166(2):219-29. Abstract
Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled Phase III DUO-O trial. ASCO 2023;Abstract LBA5506.
Hays J et al. UPGRADE: Phase 1 combination trial of the NaPi2b-directed antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer. IGCS 2022;Abstract TP024.
Hong P et al. Tumor treating fields: A comprehensive overview of the underlying molecular mechanism. Expert Rev Mol Diagn 2022;22(1):19-28. Abstract
Kristeleit RS et al. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: Final results from Study 10. Br J Cancer 2023;128(2):225-65. Abstract
Lee JY et al. Final primary analysis in the original cohort of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer. SGO 2023;Abstract 217.
Li N et al. Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME study): A randomized, double-blind, placebo-controlled, phase 3 trial. SGO 2022;Abstract LBA 5.
Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. J Clin Oncol 2023;41(13):2436-45. Abstract
Matulonis UA et al. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer. SGO 2023;Abstract 214.
Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract
Moore KN et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. ASCO 2023;Abstract LBA5507.
Oaknin A et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (Folrα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of Folrα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. ASCO 2023;Abstract 5508.
Oaknin A et al. Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. ESGO 2022;Abstract 2022-RA-660-ESGO.
Oza AM et al. Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation. ESMO 2022;Abstract 518O.
Penson R et al. Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer. SGO 2022;Abstract 26.
Randall LM et al. MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). ASCO 2022;Abstract 5573.
Ray-Coquard I et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. ESMO 2022;Abstract LBA29.
Richardson D et al. Updated results from the phase 1 expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in ovarian cancer. SGO 2022;Abstract 076.
Richardson D et al. UPLIFT (ENGOT-OV67/GOG-3048): A pivotal cohort of the XMT-1536-1 trial of upifitamab rilsodotin (XMT-1536; UPRI), a NAPI2B-directed antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer. IGCS 2022;Abstract TP036.
Richardson D et al. Up-next (GOG-3049/ENGOT-ov71-NSGO-CTU): A study of upifitamab rilsodotin (UPRI), a NaPi2b-directed antibody-drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. IGCS 2022;Abstract TP037.
Selle F et al. OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis—An exploratory joint analysis of the BRCA and non-BRCA cohorts. ASCO 2022;Abstract 5558.
Shams S, Patel CB. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]). J Mol Cell Biol 2022;14(8):mjac047. Abstract
Vergote I et al. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol 2018;150(3):471-7. Abstract
Vergote I et al. Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3. IGCS 2020;Abstract 358.
Yu Y et al. Effectiveness and safety of niraparib as neoadjuvant therapy in advanced ovarian cancer with homologous recombination deficient: A prospective, multicenter, exploratory, phase 2, single-arm study (NANT). SGO 2022;Abstract 041.